#USA #New York #Class Action #Levi Korsinsky #Altimmune

Levi & Korsinsky Notifies Altimmune, Inc. Investors of Class Action Lawsuit

Levi & Korsinsky, LLP has recently issued a notification to investors of Altimmune, Inc. regarding a class action lawsuit relating to securities fraud. The firm is urging investors impacted by the company’s alleged deceptive practices between August 2023 and June 2025 to take action before the approaching deadline for filing claims.

Background of the Case

The class action lawsuit aims to recover losses for Altimmune investors who were negatively affected by the company's alleged misrepresentation of financial and operational conditions. According to the details published, the lawsuit was initiated after a specific event, which saw a dramatic drop in the company's stock price. On June 26, 2025, Altimmune released a press statement regarding the outcomes from the IMPACT Phase 2b MASH trial concerning its lead product, Pemvidutide, intended for the treatment of Metabolic Associated Steatotic Liver Disease (MASH).

Prior to the release of these results, the firm’s executive team had reportedly provided consistently inflated expectations regarding the trial's outcomes. However, when the results revealed a failure to achieve statistical significance in important analyses, it raised concerns among investors. The press release indicated a positive trend in fibrosis improvement but failed to meet the necessary statistical criteria, ultimately attributed to a higher-than-expected placebo effect.

Market Reaction

In the immediate aftermath of this announcement, Altimmune's shares plummeted from $7.71 per share on June 25 to $3.61 the following day, marking a staggering decline of 53.2% in just one trading session. This steep drop alarmed many investors, prompting them to consider their legal options moving forward.

Important Dates

Investors who sustained losses during this critical period should note that the deadline to request appointment as lead plaintiff is set for October 6, 2025. Those who qualify may not necessarily need to serve as lead plaintiffs to share in any potential recovery resulting from this case.

Legal Assistance Offered

Levi & Korsinsky is extending its services to affected investors, offering an opportunity for compensation without any upfront costs. Individuals classified as class members could potentially receive reimbursement without needing to pay out-of-pocket expenses or fees.

The firm boasts a successful track record in pursuing justice for investors and has secured significant settlements over the past 20 years in complex securities litigation. With a dedicated team of over 70 experts, Levi & Korsinsky continues to stand out as one of the top securities litigation firms in the United States, having been featured on ISS Securities Class Action Services' Top 50 Report for several consecutive years.

How To Contact

Altimmune investors are encouraged to act swiftly and reach out to Levi & Korsinsky. For further inquiries or to clarify details about the impending deadlines, affected individuals can contact attorney Joseph E. Levi via email or phone. The firm's contact details are as follows:

• - Email: [email protected]
• - Phone: (212) 363-7500

Investors who wish to gain more information can also fill out a submission form located on their website. Time is of the essence for those wishing to preserve their rights in this ongoing matter, as their involvement is crucial in ensuring accountability for any alleged wrongdoing.

In conclusion, Levi & Korsinsky’s notice serves as a timely reminder for Altimmune investors to remain vigilant and proactive regarding their rights as shareholders. Given the complexity of securities litigation, investor engagement and understanding the implications of the class action lawsuit will be critical in navigating the challenges ahead.